QCLS
Q/CFNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-22
Current thesis
Composite grade F from latest DB weights. Momentum 12.5 / Value 41.1
Posture
Defensive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.0.
What can break
Mixed signals. Wait for cleaner trend confirmation.
Momentum
12
Value
41
Sentiment
N/A
Setup hits (3d)
0 · Net Neutral
AI TargetsBase - · Bull - · Bear -
Data freshness
Prices
As of 2026-07-22
Fundamentals
As of 2026-07-23 • Vendor: Data Vendor v1
Scores
As of 2026-07-22 • Model: HYBRID_IC_RP
AI Memo
Unavailable: No memo yet
Investment thesisAs of 2026-07-22
Investment thesis
As of 2026-07-22
Supporting evidence
What
Grade F · Defensive
Confidence Medium · Net Neutral
Target $4,835,404.81
Why
Momentum12 · Δ7d -5.2
Value41 · Δ7d -0.0
SentimentN/A · Δ7d -
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Value · See fundamentals
Momentum
12
40% active weight
Current posture
7d trendSoftening
Δ7d
-5.2
Δ21d
-37.4
Value
41
60% active weight
Current posture
7d trendFlat
Δ7d
-0.0
Δ21d
-0.1
Sentiment
N/A
Coverage pending
No current score
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade F. Momentum 12.5 / Value 41.1
Fundamentals (TTM)As of 2026-07-23
Fundamentals (TTM)
As of 2026-07-23
Market Cap
$26.31M
Beta
2.14
Shares Out
7.85M
P/E (TTM) · Derived
-0.4
P/S (TTM)
-
P/FCF (TTM) · Derived
-0.23
Rev YoY
-100.0%
EPS YoY
-99.5%
Gross Margin
+37.3%
Op Margin
-
Net Debt
-$15.79M
Current Ratio
3.71
As of 2026-07-22 • Updated nightlySource: Internal modelMethodology